Our study revealed for the first time that miR-16-1-3p inhibits tumor glycolysis by targeting PGK1 both in vitro and in vivo, thereby repressing breast cancer cell proliferation, migration, invasion, and metastasis. This evidence concerns the gene PGK1 and breast carcinoma.